After #aducanumab leaves the market in November, patients may want to switch to #lecanemab —but the right protocol for doing so is not yet known: bit.ly/4bFmn69

#NeuroTwitter #Alzheimers Knight ADRC UAB Department of Neurology Ron Petersen, M.D. First Choice Neurology UW Memory Brain Zaldy Tan

In an 18-month long study, intravenous (IV) infusion treatment with LEQEMBI (Lecanemab) was proven to slow the progress of early Alzheimer's disease.

FULL STORY: bit.ly/3JD84mL

Lecanemab is a disgusting scam. $26,000/year for a drug that causes serious adverse effects in 1.2% and symptomatic brain bleeding in 1.7%. As I predicted increasing serious adverse events in the OLE Ash Paul

alzres.biomedcentral.com/articles/10.11…

Alzheimer hastalığı tedavisinde FDA onayı alan anti-amiloid tedavi lecanemab klinik araştırmasının uzatım döneminde güvenliliğe ilişkin veriler yayınlandı📌

Bu dönemde, 9 ölüm bildirilmiş ve 4 ölümün ise doğrudan ilaç ilişkili olduğu saptanmış..

#DYK the integration of p-Tau 181 as a biomarker was key to enabling the development and approval of lecanemab as an innovative #Alzheimers disease treatment? Throughout clinical settings, blood-based biomarkers have emerged as a powerful tool. ➡️ bit.ly/49EOJMe

And after hearing about Lecanemab, additional new treatments in the horizon by Bruno Vellas, Gerard Piñol IRBLleida and Melanie Shulman Biogen, Ace Alzheimer Center Barcelona #BCNPIT24

Updated Lecanemab safety results

Just published in Alzheimer's Research & Therapy.

This analysis now also includes the open-label extension (OLE) study of the FDA-approved anti-amyloid drug Lecanemab (Leqembi).

Main new findings:

1⃣ There were 9 deaths during the OLE, with 4

Dr. Jeff Gelblum was asked by Neurology Today, 𝗪𝗵𝗮𝘁'𝘀 𝗡𝗲𝘅𝘁 𝗳𝗼𝗿 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗧𝗿𝗲𝗮𝘁𝗲𝗱 𝗪𝗶𝘁𝗵 𝗔𝗱𝘂𝗰𝗮𝗻𝘂𝗺𝗮𝗯?
American Academy of Neurology #lecanemab #dementia Alzheimer's Foundation of America Alzheimer's Association #jeffreygelblummd #alzheimers

PRESS RELEASE: Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing. bioarctic.com/en/eisai-initi…

One more study supporting that 5-8% of people with #Alzheimer ’s disease would be eligible for #lecanemab neurology.org/doi/10.1212/WN…

Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42

Alberto J Espay

Link: content.iospress.com/articles/journ…

Alzheimer bi berhevbûna ne normal ya proteîna beta-amyloid re têkildar e, ku di tevna mejî de plaketan çêdike, bandorê li ser bîr û ramanê dike.

Ji Zanîngeha Presbiteryen/Columbia ji Navenda Tibê ya Irvingê Norolog Dr. Lawrence S. Honig dibêje, Lecanemab formên taybetî yên

Over a year since its debut, the first Alzheimer's drug to slow the disease's progression - lecanemab (Leqembi) struggles in the U.S. market. Major hospitals are slow to adopt, and insurers deny coverage.
#Alzheimers #healthcare

覚悟を感じる「羅針盤」でした！すごい。
エーザイさんとの事例も紹介されています。記載のある（認知症進行予防がもたらす）介護者の負担軽減に関して、下記が参考になります。介護者のQALYに関する言及が興味深いです。

Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease

ADGAP mtg #ags24 ended w/ deep discussions related to use of monoclonal antibody (namely lecanemab/donanemab). Geriatricians need to be involved w/ inter-professional research, clinical trials, and decision-making related to these emerging AD therapies June M American Geriatrics Society

Dr. Kaitlin Willham spearheads VA San Francisco Lecanemab workgroup, crafting procedures for VA clinicians to prescribe Lecanemab safely. Dr. Helen Chen acknowledges her exceptional leadership, crucial for starting Lecanemab infusions at the VA. #geriatrics

Easton Center’s Spring 2024 Newsletter features Dr. Sánchez López’s answers to common questions about #lecanemab and the ELHA Lab, bridging science and the Latino communities in LA County.

#Alzheimers
ELHA UCLA Neurology

eastonad.ucla.edu/sites/g/files/…

Lecanemab is administered to patients through an IV infusion.

Dr. Alejandra Sanchez Lopez from UCLA Easton Center for Alzheimer's Research & Care explains the different aspects of treatment, such as frequency of doses and why patients are monitored with routine MRIs. #neurotwitter

youtu.be/uZ41G0-vARM?si…

According to this study, neither targeted lecanemab treatment nor treatment unrestricted by APOE ε4 genotype is cost-effective vs standard of care alone for patients with mild cognitive impairment or mild dementia due to Alzheimer disease: bit.ly/3IDcJEJ

#NeuroTwitter

The need to provide treatment and therapeutics for #Alzheimers has never been higher.

With the FDA approval of Lecanemab, Dr. S. Thomas Carmichael Jr. discusses how the drug recognizes & clears abnormal amyloid proteins, decelerating disease progression.

uclahealth.org/news/amyloid-a…